Current concepts in mild cognitive impairment

Archives of Neurology

Volumn 58, Issue 12, 2001, Pages 1985-1992

  Petersen, Ronald C ^a   Doody, Rachelle ^b   Kurz, Alexander ^c   Mohs, Richard C ^d   Morris, John C ^e   Rabins, Peter V ^f   Ritchie, Karen ^g   Rossor, Martin ^h   Thal, Leon ⁱ   Winblad, Bengt ^j  

^a MAYO CLINIC ROCHESTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INSERM   (France)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CYCLOOXYGENASE 2 INHIBITOR; GINKGO BILOBA EXTRACT;

AGING; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; ETHICS; GERIATRICS; HUMAN; NEUROLOGY; NEUROPATHOLOGY; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PSYCHIATRY;

EID: 0035195760     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.12.1985     Document Type: Article

References (76)

1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
2. Vassar R, Bennett BD, Babu-Khan S, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735-741.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56: 303-308.
4. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661-665.
5. Rubin DH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55:395-401.
6. Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349:763-765.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
8. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(4 suppl):S1-S2.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, for the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
10. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 1994;51:888-895.
11. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
12. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatr.1982;139:1136-1139.
13. Petersen RC. Mild cognitive impairment or questionable dementia [editorial]? Arch Neurol. 2000;57:643-644.
14. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997; 349:1793-1796.
15. Kral VA. Senescent forgetfulness: benign and malignant. CMAJ. 1962;86:257-260.
16. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S, for the National Institute of Mental Health Work Group. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Dev Neuropsychol. 1986;2:261-276.
17. Levy R. Aging-associated cognitive decline. Int Psychogeriatr. 1994;6:63-68.
18. Hanninen T, Hallikainen M, Koivisto K, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. J Am Geriatr Soc. 1995;43:1007-1015.
19. Richards M, Touchon J, Ledesert B, Richie K. Cognitive decline in aging: are AAMI and AACD distinct entities? Int J Geriatr Psychiatr. 1999;14:534-540.
20. Lane F, Snowdon J. A longitudinal survey of suburban elderly. In: Lovibond P, Wilson P, eds. Clinical and Abnormal Psychology. Amsterdam, the Netherlands: Elsevier; 1989:365-376.
21. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
22. Barker A, Jones R, Jennison C. A prevalence study of age-associated memory impairment. Br J Psychiatr. 1995;167:642-648.
23. Coria F, Gomez de Caso JA, Minguez F, Rodriquez-Artalejo F, Claveria LE. Prevalence of age-associated memory impairment and dementia in a rural community. J Neurol Neurosurg Psychiatr. 1993;56:973-976.
24. Larrabee GJ, Crook TH. Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6:95-104.
25. Smith GE, Ivnik RJ, Petersen RC, Malec JF, Kokmen E, Tangalos E. Age-associated memory impairment diagnoses: problems of reliability and concerns for terminology. Psychol Aging. 1991;6:551-558.
26. Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (≥80 years of age) humans. Acta Neuropathol (Berl). 1994;88:212-221.
27. Lippa CF, Johnson R, Smith TW. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol. 1998;43:102-106.
28. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469-490.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr. 1984;141:1356-1364.
31. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol. 1989;46:141-145.
32. Storandt M, Hill RD. Very mild senile dementia of the Alzheimer type, II: psychometric test performance. Arch Neurol. 1989;46:383-386.
33. Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and staging of dementia in Alzheimer's disease: use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol. 1992;49:448-452.
34. Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG. Memory function in very early Alzheimer's disease. Neurology. 1994;44:867-872.
35. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol. 1991;48:278-281.
36. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurotoay. 1994;44:1427-1432.
37. Dartigues JF, Commences D, Letenneur L, et al. Cognitive predictors of dementia in elderly community residents. Neuroepidemiology. 1997;16:29-39.
38. Howieson DB, Dame A, Camidoli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc. 1997;45:584-589.
39. Inouye SK, Albert MS, Mohs RC, Sun K, Berkman LF. Cognitive performance in a high-functioning community-dwelling elderly population. J Gerontol A Biol Sci Med Sci. 1993;48:M146-M151.
40. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, et al, for the Consortium to Establish a Registry for Alzheimer's Disease. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease. Neurology. 1998;51(pt 18):159-162.
41. Ferman TJ, Boeve BF, Smith GE, et al. REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology. 1999;52:951-957.
42. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786-794.
43. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397-1403.
44. Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: a longitudinal prospective study. Brain. 1998;121:1631-1639.
45. Bobinski M, de Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res. 1998;805:267-269.
46. Xu YC, Jack CR Jr, O'Brien PC, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology. 2000;54:1760-1767.
47. Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484-489.
48. Kennedy AM, Frackowiak RS, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett. 1995;186:17-20.
49. Berent S, Giordani B, Foster N, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res. 1999;33:7-16.
50. Reiman EM, Caselli RJ, Lang S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med. 1996; 334:752-758.
51. 1H MRS study. Neurology. 2000;55: 210-217.
52. Troncosco JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 1996;17:365-371.
53. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
54. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic substrate of mild cognitive impairment [abstract]. Neurobiol Aging. 2000;21(suppl 1S):S198.
55. Galasko D, Clark C, Chang L, et al. Assessment CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997;48:632-635.
56. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatr. 1998;64:298-305.
57. Sunderland T, Wolozin B, Galasko D, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46:750-755.
58. Galasko D. Cerebrospinal fluid opens a window on Alzheimer's disease. Arch Neurot. 1999;56:655-656.
59. Grundman M. Vitamin E in Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. 2000;71:630S-636S.
60. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid β-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res. 1998;62:131-140.
61. Yaffe K, Sawaya G, Liebergurg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-695.
62. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999;52:965-970.
63. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
64. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res. 1998;54:1-6.
65. Sano M, Ernesto C, Thomas RG, et al, for The Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
66. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem. 2001;44:2039-2060.
67. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999;398:513-517.
68. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999;38:3549-3558.
69. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997;278:1327-1332.
70. Christensen H, Henderson AS, Jorm AF, Mackinnon AJ, Scott R, Korten AE. ICD-10 mild cognitive disorder: epidemiological evidence on its validity. Psychol Med. 1995;25:105-120.
71. Daly E, Zaitchck D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer's disease using standardized clinical information. Arch Neurol. 2000;57:675-680.
72. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430-439.
73. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37-42.
74. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
75. Arnaiz A, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851-855.
76. Petersen RC, Stevens J, Ganguli M, Tangalos EG, Cummings J, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment. Neurology. 2001;56:1133-1142.